Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning

Journal of the American College of Cardiology

Volumn 48, Issue 4, 2006, Pages 700-707

  Riksen, Niels P ^a   Zhou, Zhigang ^a   Oyen, Wim J G ^a   Jaspers, Rogier ^a   Ramakers, Bart P ^a   Brouwer, Rene M H J ^a   Boerman, Otto C ^a   Steinmetz, Neil ^b   Smits, Paul ^a   Rongen, Gerard A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b North American Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANNEXIN; ANNEXIN A5 TC 99M; CAFFEINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; HEART ATRIUM MUSCLE; HEART INFARCTION PREVENTION; HEART MUSCLE CONTRACTILITY; HEART SURGERY; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RANDOMIZATION; REPERFUSION INJURY; SCINTIGRAPHY; SIMULATION; THENAR;

ADULT; ANNEXIN A5; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; HUMANS; ISCHEMIC PRECONDITIONING; MALE; MUSCLE, SKELETAL; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, PURINERGIC P1; REPERFUSION INJURY;

EID: 33746813097     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.04.083     Document Type: Article

References (35)

1. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia. a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
2. Yellon D.M., and Downey J.M. Preconditioning the myocardium. from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
3. Tomai F., Crea F., Chiariello L., and Gioffre P.A. Ischemic preconditioning in humans. models, mediators, and clinical relevance. Circulation 100 (1999) 559-563
4. Liu G.S., Thornton J., Van Winkle D.M., Stanley A.W., Olsson R.A., and Downey J.M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84 (1991) 350-356
5. Liu G.S., Richards S.C., Olsson R.A., Mullane K., Walsh R.S., and Downey J.M. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28 (1994) 1057-1061
6. Carr C.S., Hill R.J., Masamune H., et al. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 36 (1997) 52-59
7. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51 (1999) 83-133
8. Rongen G.A., Oyen W.J.G., Ramakers B.P., et al. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation 111 (2005) 173-178
9. Speechly-Dick M.E., Grover G.J., and Yellon D.M. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 77 (1995) 1030-1035
10. Barone J.J., and Roberts H.R. Caffeine consumption. Food Chem Toxicol 34 (1996) 119-129
11. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., and van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84 (1994) 1415-1420
12. Martin S.J., Reutelingsperger C.P., McGahon A.J., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus. inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182 (1995) 1545-1556
13. Dumont E.A., Reutelingsperger C.P., Smits J.F., et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 7 (2001) 1352-1355
14. Hofstra L., Liem I.H., Dumont E.A., et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356 (2000) 209-212
15. Hofstra L., Dumont E.A., Thimister P.W., et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA 285 (2001) 1841-1842
16. Piot C.A., Padmanaban D., Ursell P.C., Sievers R.E., and Wolfe C.L. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 96 (1997) 1598-1604
17. Riksen N.P., Oyen W.J., Ramakers B.P., et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 78 (2005) 52-59
18. Bell S.P., Sack M.N., Patel A., Opie L.H., and Yellon D.M. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 36 (2000) 2296-2302
19. Cleveland Jr. J.C., Meldrum D.R., Cain B.S., Banerjee A., and Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96 (1997) 29-32
20. Morris S.D., and Yellon D.M. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 29 (1997) 1599-1606
21. Liu Y., Ytrehus K., and Downey J.M. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol 26 (1994) 661-668
22. Gross G.J., and Auchampach J.A. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70 (1992) 223-233
23. Schultz J.E., Rose E., Yao Z., and Gross G.J. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268 (1995) H2157-H2161
24. Zaugg M., Lucchinetti E., Garcia C., Pasch T., Spahn D.R., and Schaub M.C. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth 91 (2003) 566-576
25. Persson C.G., Erjefalt I., and Andersson K.E. Positive inotropic and chronotropic effects and coronary vasodilation in vitro by two antiasthmatic xanthines with different abilities to antagonize adenosine. J Cardiovasc Pharmacol 5 (1983) 778-785
26. Lin C.I., Chiu T.H., Chiang B.N., and Cheng K.K. Electromechanical effects of caffeine in isolated human atrial fibres. Cardiovasc Res 19 (1985) 727-733
27. Collis M.G., Keddie J.R., and Torr S.R. Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockade. Br J Pharmacol 81 (1984) 401-407
28. Smits P., Thien T., and van't Laar A. The cardiovascular effects of regular and decaffeinated coffee. Br J Clin Pharmacol 19 (1985) 852-854
29. Smits P., Pieters G., and Thien T. The role of epinephrine in the circulatory effects of coffee. Clin Pharmacol Ther 40 (1986) 431-437
30. Greenland S. A meta-analysis of coffee, myocardial infarction, and coronary death. Epidemiology 4 (1993) 366-374
31. Kawachi I., Colditz G.A., and Stone C.B. Does coffee drinking increase the risk of coronary heart disease? Results from a meta-analysis. Br Heart J 72 (1994) 269-275
32. Cornelis M.C., El-Sohemy A., Kabagambe E.K., and Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295 (2006) 1135-1141
33. Robertson D., Wade D., Workman R., Woosley R.L., and Oates J.A. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 67 (1981) 1111-1117
34. James J.E. Critical review of dietary caffeine and blood pressure. a relationship that should be taken more seriously. Psychosom Med 66 (2004) 63-71
35. Lovallo W.R., Wilson M.F., Vincent A.S., Sung B.H., McKey B.S., and Whitsett T.L. Blood pressure response to caffeine shows incomplete tolerance after short-term regular consumption. Hypertension 43 (2004) 760-765